Research suggests that lactoferrin plays a meaningful role in supporting gut health across multiple dimensions, including modulating the gut microbiome toward beneficial bacteria, reducing intestinal inflammation, supporting gut barrier integrity, and contributing to healthy immune development in the digestive tract. The evidence base includes randomized controlled trials, reviews, and mechanistic studies, with the most clinically notable findings coming from a placebo-controlled trial in children with environmental enteric dysfunction that observed improvements in intestinal permeability and significant reductions in hospitalization and acute malnutrition, and from reviews of its role in infant gut development and protection against serious conditions like necrotizing enterocolitis. Studies also indicate that lactoferrin may work synergistically with other bioactive compounds — such as osteopontin or retinoic acid — to enhance microbial and immune benefits, and conference-level research continues to expand understanding of how lactoferrin's source, iron content, and formulation affect its effectiveness. However, several of the supporting studies are reviews or preclinical and mechanistic in nature rather than large human trials, some proposed combinations lack direct experimental testing, and a number of studies in the collection examined lactoferrin primarily as a biomarker of gut inflammation rather than as a therapeutic agent, so the overall evidence, while promising, remains preliminary in several areas and warrants further large-scale clinical investigation.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Lactoferrin-osteopontin complexes: insights into intestinal organoid bioavail... | Other | 2025 | Supports | 100 |
| Synergistic Effect of Retinoic Acid and Lactoferrin in the Maintenance of Gut... | Review | 2024 | Supports | 95 |
| Lactoferrin in the Eternal City. | Review | 2025 | Supports | 90 |
| Antibodies and Inflammation: Fecal Biomarkers of Gut Health in Domestic Rumin... | Other | 2025 | Neutral | 85 |
| Longitudinal flux balance analyses of a patient with Crohn’s disease highligh... | Other | 2022 | Neutral | 85 |
| Proteomic analysis of human milk reveals nutritional and immune benefits in t... | Other | 2022 | Neutral | 80 |
| Clinical Benefits of Lactoferrin for Infants and Children. | Review | 2016 | Supports | 80 |
| From gut health to nutrient digestion and metabolism: An integrative biomarke... | Other | 2026 | Neutral | 75 |
| Targeting of the human nasal microbiota by secretory IgA antibodies | Other | 2022 | Neutral | 75 |
| Bioactive Factors in Human Breast Milk Attenuate Intestinal Inflammation duri... | Review | 2020 | Supports | 70 |
| Gut biomolecules (I-FABP, TFF3 and lipocalin-2) are associated with linear gr... | Other | 2022 | Neutral | 65 |
| Determination of Bovine Lactoferrin in Powdered Infant Formula and Adult Nutr... | Other | 2024 | Neutral | 60 |
| Supplementation With Lactoferrin and Lysozyme Ameliorates Environmental Enter... | RCT | 2019 | Supports | 55 |
| Mechanisms Affecting the Gut of Preterm Infants in Enteral Feeding Trials. | Other | 2017 | Neutral | 50 |
| Koumiss (Fermented Mare's Milk) as a Functional Food: Bioactive Proteins, Pep... | Review | 2025 | Supports | 45 |
| Effects of lactoferrin supplementation on ileal and total tract nutrient dige... | Other | 2006 | — | 40 |
| Consumption of lysozyme-rich milk can alter microbial fecal populations. | Other | 2012 | Neutral | 35 |
| Supplemented Infant Formula and Human Breast Milk Show Similar Patterns in Mo... | Other | 2024 | Supports | 30 |